Estrella Immunopharma earnings were -$13.1M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest ESLA earnings report on Dec 31, 2025 announced Q4 2025 earnings of -$613.2k, down 87.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ESLA reported annual earnings of -$13.1M, with 78.7% growth.
Estrella Immunopharma Earnings Reports & History FAQ
What were Estrella Immunopharma's earnings last quarter?
Estrella Immunopharma (NASDAQ: ESLA) reported Q4 2025 earnings per share (EPS) of -$0.01, up 66.67% year over year. Total ESLA earnings for the quarter were -$613.17 thousand. In the same quarter last year, Estrella Immunopharma's earnings per share (EPS) was -$0.03.
Is Estrella Immunopharma profitable or losing money?
As of the last Estrella Immunopharma earnings report, Estrella Immunopharma is currently losing money. Estrella Immunopharma's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$13.06 million, a 47.65% increase year over year.
What was ESLA's earnings growth in the past year?
As of Estrella Immunopharma's earnings date in Q1 2026, Estrella Immunopharma's earnings has grown year over year. ESLA earnings in the past year totalled -$13.06 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.